- Home
- GENK vs CTXR Comparison
GENK vs CTXR Comparison
Compare GENK & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GENK | CTXR |
|---|---|---|
| Founded | 2011 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1M | 16.6M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | GENK | CTXR |
|---|---|---|
| Price | $1.79 | $0.90 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | $5.67 | ★ $6.00 |
| AVG Volume (30 Days) | 40.9K | ★ 369.5K |
| Earning Date | 03-05-2026 | 02-11-2026 |
| Dividend Yield | ★ 1.62% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $217,449,000.00 | N/A |
| Revenue This Year | $8.46 | N/A |
| Revenue Next Year | $8.17 | $147.57 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 9.36 | N/A |
| 52 Week Low | $1.85 | $0.63 |
| 52 Week High | $7.41 | $2.97 |
Technical Indicators
Market Signals| Indicator | GENK | CTXR |
|---|---|---|
| Relative Strength Index (RSI) | 28.50 | 54.63 |
| Support Level | $1.86 | $0.70 |
| Resistance Level | $2.11 | $0.85 |
| Average True Range (ATR) | 0.13 | 0.07 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 10.45 | 90.00 |
Price Performance
Historical ComparisonAbout GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. It operates 43 Gen Korean BBQ restaurants in the United States.
About CTXR Citius Pharmaceuticals Inc.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.